# Recall of Low-Dose Vapes and Pre-Rolls Due to Mislabeled THC Content > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/mislabeled-thc-products-recall-safety-risks/ > **Published:** 2026-03-12T17:56:37-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:08:30-04:00 > **Clinical Summary:** Mislabeled THC products pose safety risks, prompting recalls of low-dose vapes and pre-rolls with excessive THC content. Learn about dosing and testing. --- ✦ New CED Clinical Relevance #35 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. THCDosingSafetyIndustry Why This Matters Mislabeled THC products pose direct safety risks to patients who rely on accurate dosing information to manage symptoms or avoid adverse effects, particularly vulnerable populations like older adults or those new to [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). Clinicians should counsel patients that product labeling accuracy remains inconsistent across markets, requiring verification through third-party testing or consultation with dispensary staff before recommending specific cannabis products. These recalls underscore the clinical importance of documenting baseline THC exposure and monitoring patients for unexpected dose-related effects like anxiety, impaired cognition, or cannabis hyperemesis syndrome. Clinical Summary A recent product recall has identified mislabeled cannabis vapes and pre-rolls that were marketed as low-dose but contained significantly higher THC concentrations than labeled. This quality control failure highlights ongoing challenges in cannabis product standardization and accurate labeling across the industry, which directly impacts clinicians’ ability to recommend precise dosing to patients seeking therapeutic or controlled effects. Patients who purchased these products under the assumption they were receiving low-dose formulations may have inadvertently consumed excessive amounts of THC, potentially experiencing unwanted adverse effects or toxicity. The recall underscores the importance of third-party testing verification and regulatory oversight in the cannabis market, particularly for products intended for medical use or careful dose titration. Clinicians should remain vigilant about product labeling accuracy when counseling patients on [cannabis dosing](https://cedclinic.com/medical-cannabis-safety-facts/) and should advise patients to verify testing certificates and purchase from regulated dispensaries with quality assurance measures. Patients and clinicians alike should request and review independent laboratory testing results for any cannabis product before use to ensure actual potency matches labeled claims. Dr. Caplan’s Take “When patients buy a product labeled as low-dose, they’re making a conscious clinical decision based on that information, and mislabeling undermines both their autonomy and safety, particularly for those with lower tolerance or [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) who specifically chose that product for that reason. This is exactly why we need mandatory, third-party testing and real consequences for companies that misrepresent potency.” Clinical Perspective This recall of mislabeled cannabis products highlights a critical gap in product quality assurance and labeling accuracy that clinicians should be aware of when counseling patients. Patients purchasing what they believe to be low-dose formulations for symptom management or harm reduction may inadvertently consume significantly higher THC concentrations, potentially leading to unexpected adverse effects including acute anxiety, tachycardia, or impaired cognition—particularly concerning for older adults, those with cardiovascular disease, or patients on drug interactions. The inconsistency between labeled and actual THC content underscores the importance of discussing cannabis sourcing, testing standards, and the variable regulatory oversight across jurisdictions with patients who use or are considering cannabis products. Clinicians should remain cognizant that even well-intentioned patients may be consuming products that deviate substantially from their stated composition, complicating symptom attribution and dosing discussions. When evaluating adverse effects or treatment 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Low-dose+vapes%2C+pre-rolls+recalled+for+having+too+much+THC+in+them+-+FOX+9+%40drcaplan&url=https%3A%2F%2Fwww.fox9.com%2Fnews%2Flow-dose-vapes-pre-rolls-recalled-having-too-much-thc-them)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.fox9.com%2Fnews%2Flow-dose-vapes-pre-rolls-recalled-having-too-much-thc-them)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Low-dose+vapes%2C+pre-rolls+recalled+for+having+too+much+THC+in+them+-+FOX+9+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.fox9.com%2Fnews%2Flow-dose-vapes-pre-rolls-recalled-having-too-much-thc-them)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.fox9.com/news/low-dose-vapes-pre-rolls-recalled-having-too-much-thc-them](https://www.fox9.com/news/low-dose-vapes-pre-rolls-recalled-having-too-much-thc-them) Further Reading CED Clinic Blog[Cannabis-Infused Beverages as Alcohol Alternatives: New York at Five Years](https://cedclinic.com/cannabis-beverage-substitution-alcohol-new-york-five-years/) Research Digest[AM Policy Update: March 11, 2026](https://cedclinic.com/dea-rescheduling-marijuana-march-11-2026/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 12, 2026](https://cedclinic.com/cannabis-regulatory-updates-march-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Minnesota cannabis officials recall Tidal Wave THC vapes for high THC content – KSTP](https://cedclinic.com/tidal-wave-vape-recall-minnesota-high-thc-content/) Learn about a recent recall of Tidal Wave THC vapes due to excessive THC levels, highlighting ongoing challenges in cannabis product safety. [Read More](https://cedclinic.com/tidal-wave-vape-recall-minnesota-high-thc-content/) [Missouri attorney general warns of unsafe, mislabeled cannabis products | ksdk.com](https://cedclinic.com/missouri-cannabis-product-safety-warning/) Explore warnings from Missouri officials about mislabeled cannabis products and the importance of regulatory oversight. [Learn More](https://cedclinic.com/missouri-cannabis-product-safety-warning/) [What's in your weed? Study finds issues with labelling, tracking cannabis](https://cedclinic.com/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis/) A study reveals significant issues with cannabis product labeling and tracking, underscoring the need for quality assurance. [Discover Insights](https://cedclinic.com/whats-in-your-weed-study-finds-issues-with-labelling-tracking-cannabis/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).